{
    "clinical_study": {
        "@rank": "87348", 
        "arm_group": [
            {
                "arm_group_label": "Enzalutamide tablet", 
                "arm_group_type": "Experimental", 
                "description": "Multiple once daily oral doses of enzalutamide formulated as a tablet for approximately 8 weeks"
            }, 
            {
                "arm_group_label": "Enzalutamide capsule", 
                "arm_group_type": "Active Comparator", 
                "description": "Multiple once daily oral doses of  enzalutamide formulated as liquid-filled soft gelatin capsule for approximately 8 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "A multiple dose relative bioavailability study in patients with prostate cancer comparing a\n      capsule and a tablet formulation of enzalutamide."
        }, 
        "brief_title": "Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Prostate Cancer", 
            "Pharmacokinetics of Enzalutamide"
        ], 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed prostate cancer (all stages) for whom androgen deprivation\n             therapy is indicated (except when indicated in a neoadjuvant/adjuvant setting).\n             Subjects may be on ongoing androgen deprivation therapy with a gonadotropin releasing\n             hormone (GnRH) analogue or orchiectomy (i.e., medical or surgical castration) at\n             study entry.\n\n          -  Progressive disease by Prostate-specific antigen (PSA) or imaging. Disease\n             progression for study entry is defined as one or more of the following 3 criteria:\n\n               -  PSA progression defined by a minimum of 2 rising PSA levels with an interval of\n                  \u22651 week between each determination. The PSA value during the pre-investigational\n                  period should be \u22652 \u03bcg/L (2 ng/mL);\n\n               -  Soft tissue disease progression defined by the Response Evaluation Criteria in\n                  Solid Tumors, version 1.1 (RECIST 1.1) for soft tissue disease\n\n               -  Bone disease progression defined by two or more new lesions on bone scan\n\n        Exclusion Criteria:\n\n          -  Treatment with chemotherapy within 4 weeks prior to enrollment (Day 1 visit) or plans\n             to initiate treatment with chemotherapy during the study.\n\n          -  History of seizure or any condition that may predispose to seizure. Also, history of\n             loss of consciousness, or transient ischemic attack within 12 months prior to\n             enrollment (Day 1 visit).\n\n          -  Patients who previously received treatment with Enzalutamide.\n\n          -  Concomitant use of drugs that are potent inducers and/or inhibitors of CYP3A4  and\n             CYP2C8.\n\n          -  Confirmed CYP2C8 poor metabolizer status based on genotyping analysis."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "27", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01902251", 
            "org_study_id": "9785-CL-0003"
        }, 
        "intervention": [
            {
                "arm_group_label": "Enzalutamide tablet", 
                "description": "Oral", 
                "intervention_name": "Enzalutamide tablet", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Xtandi", 
                    "MDV3100"
                ]
            }, 
            {
                "arm_group_label": "Enzalutamide capsule", 
                "description": "Oral", 
                "intervention_name": "Enzalutamide capsule", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Xtandi", 
                    "MDV3100"
                ]
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Phase 1", 
            "Prostate cancer", 
            "Bioavailability", 
            "Food effect", 
            "Pharmacokinetics", 
            "Xtandi", 
            "Enzalutamide", 
            "MDV3100"
        ], 
        "lastchanged_date": "November 11, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }, 
                    "name": "University of Colorado - Anschutz Medical Campus"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60637"
                    }, 
                    "name": "University of Chicago Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15232"
                    }, 
                    "name": "University of Pittsburgh Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "South Texas Accelerated Research Therapeutics"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I, Open-label, Randomized, Parallel, Relative Bioavailability Study Comparing a Capsule and a Tablet Formulation of Enzalutamide Following Multiple Once Daily Doses of 160 mg Enzalutamide in Male Subjects With Prostate Cancer", 
        "overall_official": {
            "affiliation": "Astellas Pharma Europe B.V.", 
            "last_name": "Clinical Study Manager", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Day 56 (fasted) Cmax under steady state conditions of enzalutamide", 
                "measure": "Pharmacokinetic profile of Enzalutamide under fasted conditions measured by Cmax (Maximum concentration)", 
                "safety_issue": "No", 
                "time_frame": "Day1 through  Day 56 (12 samples)"
            }, 
            {
                "description": "Day 56 (fasted) AUC0-24h under steady state conditions of enzalutamide", 
                "measure": "Pharmacokinetic profile of Enzalutamide under fasted conditions measured by AUC0-24h (Area under the concentration-time curve 0-24h)", 
                "safety_issue": "No", 
                "time_frame": "Day1 through  Day 56 (12 samples)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01902251"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Measured by: Cmax, tmax (Time to attain Cmax), AUC0-24h, Ctrough (Trough concentration), PTR (Peak-trough ratio), CLss/F (Apparent clearance at steady state)", 
                "measure": "Pharmacokinetic profile of Enzalutamide under fasted and fed conditions", 
                "safety_issue": "No", 
                "time_frame": "Day 1, 8, 29, 55, 56 and 57 (38 samples)"
            }, 
            {
                "description": "Measured by: Ctrough, Cmax, tmax, AUC0-24h, Ctrough (24h after dosing), PTR", 
                "measure": "Pharmacokinetic profile of MDPC0001 alone, MDPC0002 alone and sum of Enzalutamide plus MDPC0002", 
                "safety_issue": "No", 
                "time_frame": "Day 8, 29, 55, 56 and 57 (26 samples)"
            }, 
            {
                "measure": "Evaluation of the safety and tolerability of two oral formulations of Enzalutamide assessed through vital signs, adverse events, electrocardiogram and clinical laboratory assessments", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 58"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "collaborator": {
                "agency": "Medivation, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Astellas Pharma Europe B.V.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}